OSE Immuno Shares Soar 21% Following Key FDA Designation
OSE Immunotherapeutics surged this Monday, April 27, 2026, at midday, driven by the announcement of an orphan drug designation granted by the FDA to its partner Veloxis Pharmaceuticals. The stock is up 21.56% at 3.676 euros, sharply contrasting with the trend in the European pharmaceutical sector, with Sanofi and UCB respectively down 0.40% and 0.42% during the session.
FDA Recognizes the Potential of Pegrizeprument in Heart Transplant
Today's catalyst is clearly identified: the American drug agency has granted orphan drug status to pegrizeprument (VEL-101) for the prevention of heart transplant rejection. This anti-rejection treatment, developed by Veloxis Pharmaceuticals in partnership with OSE Immuno, had already received the same recognition for liver transplants a few months ago. This dual designation strengthens the clinical credibility of the molecule and could lead to regulatory benefits, including a few years of commercial exclusivity in the United States after a possible market launch. The announcement comes just two days before the publication of the annual results for 2025, scheduled for Wednesday, April 29, followed the next day, Thursday, April 30, by a report on the cash position for the first quarter of 2026. These closely spaced deadlines will be scrutinized, as financial visibility is a central issue for this biotech whose share price has fallen 35.73% over the year.
Technical Overbought Signal After a Sharp Rebound
From a graphical perspective, today's session marks a break. The stock is trading at 3.676 euros, above the upper Bollinger band set at 3.36 euros, which constitutes a classic potential overbought signal. This configuration reflects the unusual magnitude of the bullish movement relative to the recent volatility of the stock. Moreover, the price has just reached its 50-day moving average, located at 3.66 euros, a level that now serves as a short-term reference point. The nearest technical resistance is at 3.81 euros, while the 200-day moving average remains distant, at 5.14 euros, highlighting the extent of the correction suffered in recent months. Meanwhile, major pharmaceutical stocks in the US closed lower, with Eli Lilly down 3.67%, Johnson & Johnson by 1.37%, and AbbVie by 1.11%, underscoring that OSE Immuno's rebound is counter to the sector trend.
